All In Biotech

Drug Trial Radar · NCT02034708

Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors

Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors

Last checked: Nov 20, 2026Latest source record: Dec 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 279 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

279

Actual

Start

Jun 2014

Primary completion

Sep 2015

Study completion Sep 2015

Sponsor

Lead sponsor
GuerbetIndustry
Sponsor type
Industry
First posted
Jan 13, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate non-inferiority of Dotarem®-enhanced MRI as compared to Gadovist®/ Gadavist®-enhanced MRI in the diagnosis of brain tumors in terms of overall lesion visualization and characterization (off-site assessment). 270 patients will be randomized between 2 arms defining the sequence of administration of the contrast agents at the dose of 0.1mmol/kg, with a minimum of 48 hours and a maximum of 14 days in between. Each patient will, therefore, receive two MRI during his/her participation in the study. The two arms consist in : * Dotarem® in the first MRI, then Gadovist®/Gadavist® in the second MRI. * Gadovist®/Gadavist® in the first MRI, then Dotarem® in the second MRI. Contrast-enhanced MRIs will be performed on 1.5 or 3 Tesla systems. MRI examinations will be evaluated centrally by blinded independent readers for the main evaluation criterion.

Conditions

  • Primary Brain Tumor

Interventions

  • Dotarem®Drug

    Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.

  • Gadovist®/Gadavist®Drug

    Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients With Overall Lesion Visualization and Characterization Scored as Good or ExcellentTime frame: Up to 15 days after randomization

Locations

32 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Arizona Medical Center

    Tucson, Arizona

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Infinity Clinical Research, LLC

    Hollywood, Florida

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Quest Research Institute

    Farmington Hills, Michigan

  • Spectrum Health

    Grand Rapids, Michigan

  • Washington University

    St Louis, Missouri

  • Winthrop University Hospital Clinical Trials Center

    Mineola, New York

  • Temple University Hospital

    Philadelphia, Pennsylvania

  • MUSC (Medical University of South Carolina)

    Charleston, South Carolina

  • UVM MRI Center for Biomedical Imaging

    Burlington, Vermont

  • University of Washington Medical Center

    Seattle, Washington

  • Fundacion Abood Shaio

    Bogotá, Colombia

  • Fundacion Cardioinfantil Instituto de Cardiologia

    Bogotá, Colombia

  • Instituto Nacional de Cancerologia

    Bogotá, Colombia

  • Centro Medico Imbanaco

    Cali, Colombia

  • Fundacion Instituto de Alta Tecnologia Medica de Antioquia IATM

    Medellín, Colombia

  • Hospital Pablo Tobon Uribe

    Medellín, Colombia

  • Centro Regiomontano de Investigacion S.C.

    Monterrey, Mexico

  • Clinical Research Institute S.C.

    Tlanepantla, Mexico

  • Hospital CIMA

    Chihuahua City, Chihuahua, Mexico

  • Morales Vargas Centro de Investigación S.C.

    León, Guanajuato, Mexico

  • Centro Neurologico ABC

    México, Mexico Distrito Federal, Mexico

  • Hospital Universitario Dr. Jose Eleuterio Gonzalez

    Monterrey, Nuevo León, Mexico

  • Winsett Rethman S.A. de C.V.

    Monterrey, Nuevo León, Mexico

  • Ajou University Hospital

    Suwon, South Korea

  • Chonbuk national Univ Hosp

    Jeonju, Jeollabuk-do, South Korea

  • Chungbuk National University

    Cheongju-si, North Chungcheong, South Korea

  • Seoul St.Mary Hospital

    Seoul, Seocho-gu, South Korea

  • Asan medical center

    Seoul, Songpa-Gu, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.